Apogee Therapeutics (APGE) Cash from Investing Activities (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Cash from Investing Activities data on file, last reported at -$35.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 372.29% year-over-year to -$35.3 million in Q1 2026; TTM through Mar 2026 was -$227.9 million, a 3.32% increase from a year earlier, with the FY2025 full-year figure at -$179.6 million, up 40.23% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$35.3 million, up from -$288.6 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for APGE reached as high as $78.1 million in Q2 2025 and fell as low as -$288.6 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$55.5 million across 4 years, with a median of -$37.5 million in 2023.
• Across the five-year window, Cash from Investing Activities soared 216.82% in 2024 and plunged 722.48% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$39.7 million in 2023, then surged by 216.82% to $46.4 million in 2024, then tumbled by 722.48% to -$288.6 million in 2025, then soared by 87.75% to -$35.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$35.3 million in Q1 2026, -$288.6 million in Q4 2025, and $17.9 million in Q3 2025.